๐”– Scriptorium
โœฆ   LIBER   โœฆ

๐Ÿ“

Handbook of Statistics in Clinical Oncology, Second Edition

โœ Scribed by John Crowley, Donna Ankerst


Publisher
Chapman and Hall/CRC
Year
2005
Tongue
English
Leaves
592
Edition
2
Category
Library

โฌ‡  Acquire This Volume

No coin nor oath required. For personal study only.

โœฆ Synopsis


A compendium of cutting-edge statistical approaches to solving problems in clinical oncology, Handbook of Statistics in Clinical Oncology, Second Edition focuses on clinical trials in phases I, II, and III, proteomic and genomic studies, complementary outcomes and exploratory methods. Cancer Forum called the first edition a ะฒะ‚ัšะ’ั˜good reference book for statisticians who will be designing and analyzing cancer trials." The second edition includes over 1000 references, more than forty world-renowned contributors, and 300 equations, tables, and drawings.

During the five years since publication of the first edition, there has been an explosion in the technological capabilities supporting genomic and proteomic research, which are is now firmly implanted in clinical oncology. Reflecting these developments, the second edition contains a new section devoted to analyses of high-throughput data and bioinformatics. Previous chapters of the first edition have been revised to reflect current state of the art in their respective domains. The intended audience is primarily statisticians working in cancer and more generally, in any discipline of medicine. But oncologists too will find the material accessible and will benefit from a rudimentary understanding of the fundamental concepts laid forth in each chapter.

Completely revised while keeping the features that made the first edition a bestseller, this is the best single source for up-to-date statistical approaches to research in clinical medicine. More than just an update of the handbook that became the gold standard, this second edition brings you fully into the genomic era of medicine.


๐Ÿ“œ SIMILAR VOLUMES


Handbook of Statistics in Clinical Oncol
โœ John Crowley, Donna Pauler Ankerst ๐Ÿ“‚ Library ๐Ÿ“… 2006 ๐Ÿ› Chapman and Hall CRC ๐ŸŒ English

A compendium of cutting-edge statistical approaches to solving problems in clinical oncology, Handbook of Statistics in Clinical Oncology, Second Edition focuses on clinical trials in phases I, II, and III, proteomic and genomic studies, complementary outcomes and exploratory methods. Cancer Forum c

Handbook of Statistics in Clinical Oncol
โœ John Crowley, Antje Hoering ๐Ÿ“‚ Library ๐Ÿ“… 2001 ๐Ÿ› Marcel Dekker ๐ŸŒ English

Southwest Oncology Group Statistical Center, Seattle, WA. Compendium of statistical approaches to the problems facing researchers. Focuses on cancer clinical trials, with a few contributions applying to observational studies. For statisticians working in cancer research and also oncologists. Expande

Handbook of Statistics in Clinical Oncol
โœ John Crowley (ed.) ๐Ÿ“‚ Library ๐Ÿ“… 2001 ๐ŸŒ English

This book compiles state-of-the-art statistical approaches to solving problems in clinical oncology, focusing on clinical trials in phases I, II, and III, as well as quality of life and economic analyses, and exploratory methods. Examines trial design treatment based on toxicity and survival! Featur

Handbook of Statistics in Clinical Oncol
โœ John Crowley (ed.) ๐Ÿ“‚ Library ๐Ÿ“… 2001 ๐Ÿ› Marcel Dekker ๐ŸŒ English

This book compiles state-of-the-art statistical approaches to solving problems in clinical oncology, focusing on clinical trials in phases I, II, and III, as well as quality of life and economic analyses, and exploratory methods. Examines trial design treatment based on toxicity and survival! Featur

Handbook of statistics in clinical oncol
โœ Hoering, Antje; Crowley, John ๐Ÿ“‚ Library ๐Ÿ“… 2012 ๐Ÿ› Taylor & Francis/CRC Press ๐ŸŒ English

Many new challenges have arisen in the area of oncology clinical trials. New cancer therapies are often based on cytostatic or targeted agents, which pose new challenges in the design and analysis of all phases of trials. The literature on adaptive trial designs and early stopping has been exploding